ISDA

Deposition Date 2016-11-25

Release Date 2017-08-30

Last Version Date 2024-11-13

Entry Detail

PDB ID:

5MHP

Keywords:

HYDROLASE

Title:

Novel Imidazo[1,2-a]pyridine Derivatives with Potent Autotaxin/ENPP2 Inhibitor Activity

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Homo sapiens

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.43 Å

R-Value Free:

0.24

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Ectonucleotide pyrophosphatase/phosphodiesterase family member 2
Gene (Uniprot):ENPP2
Mutations:S493P
Chain IDs:A
Chain Length:871
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q13822 Pfam ID:PF01033, PF01663, PF01223 EC:3.1.4.39

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
NAG	B	NAG	-D

Ligand Molecules

7NB

IOD

NAG

PO4

SCN

Primary Citation

Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis.

Desroy, N, Housseman, C, Bock, X, Joncour, A, Bienvenu, N, Cherel, L, Labeguere, V, Rondet, E, Peixoto, C, Grassot, J.M, Picolet, O, Annoot, D, Triballeau, N, Monjardet, A, Wakselman, E, Roncoroni, V, Le Tallec, S, Blanque, R, Cottereaux, C, Vandervoort, N, Christophe, T, Mollat, P, Lamers, M, Auberval, M, Hrvacic, B, Ralic, J, Oste, L, van der Aar, E, Brys, R, Heckmann, B.Show

J. Med. Chem. 60 3580 3590 (2017)

PMID: 28414242 DOI: 10.1021/acs.jmedchem.7b00032

Abstact

Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disease areas including pulmonary fibrosis. Structural modifications of the known autotaxin inhibitor lead compound 1, to attenuate hERG inhibition, remove CYP3A4 time-dependent inhibition, and improve pharmacokinetic properties, led to the identification of clinical candidate GLPG1690 (11). Compound 11 was able to cause a sustained reduction of LPA levels in plasma in vivo and was shown to be efficacious in a bleomycin-induced pulmonary fibrosis model in mice and in reducing extracellular matrix deposition in the lung while also reducing LPA 18:2 content in bronchoalveolar lavage fluid. Compound 11 is currently being evaluated in an exploratory phase 2a study in idiopathic pulmonary fibrosis patients.

Legend

Protein

Chemical

Disease

Primary Citation of related structures